低剂量异维A酸对增生性玻璃体视网膜病变的作用:DELIVER试验
DELIVER试验是一项前瞻性、开放标签、双队列研究,以病理匹配的历史对照为对照,评估口服低剂量异维A酸(每日20 mg,持续12周)在孔源性视网膜脱离修复术后降低增生性玻璃体视网膜病变(PVR)风险的效果。结果显示,在具有PVR高危特征的原发性孔源性视网膜脱离眼中,单次手术解剖成功率显著提高(84.5% vs 61.1%,p=0.005);在复发性PVR相关视网膜脱离眼中,单次手术成功率无显著差异(78.4% vs 70.0%,p=0.358)。
要点
- 高危原发性RRD眼术后口服异维A酸12周,单次手术成功率显著高于历史对照。
- 复发性PVR相关RRD眼未见单次手术成功率的显著改善。
- 最常见副作用为皮肤/黏膜干燥(106例,97.2%)。
核心结论
- 在本研究的剂量和疗程下,口服异维A酸可能降低具有PVR高危特征的原发性孔源性视网膜脱离眼发生PVR相关复发性视网膜脱离的风险。
研究设计与样本
- 前瞻性、开放标签、双队列研究,以病理匹配的历史对照为对照。
- 实验组包括51只复发性PVR相关视网膜脱离眼和58只具有PVR高危特征的原发性视网膜脱离眼。
主要发现
- 复发性PVR相关视网膜脱离眼:单次手术解剖成功率78.4% vs 历史对照70.0%(p=0.358)。
- PVR高危原发性视网膜脱离眼:单次手术成功率84.5% vs 历史对照61.1%(p=0.005)。
- 实验组最常见异维A酸相关副作用为皮肤/黏膜干燥106例(97.2%),睡眠/梦境异常4例(3.7%),乏力3例(2.8%)。
关键数值与推荐
- 实验组自手术修复次日起口服异维A酸20 mg每日一次,持续12周。
- 主要结局指标为研究手术后3个月的单次手术解剖成功率。
临床怎么用
- 对于具有PVR高危特征的原发性孔源性视网膜脱离患者,可考虑术后口服低剂量异维A酸以降低PVR相关复发性视网膜脱离风险。
- 用药期间需关注皮肤/黏膜干燥等常见副作用。
局限性
- 本研究为开放标签设计,非随机对照,采用历史对照。
- 复发性PVR相关视网膜脱离队列未显示显著获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To examine the effect of low-dose, oral isotretinoin in lowering the risk of proliferative vitreoretinopathy (PVR) following rhegmatogenous retinal detachment (RRD) repair. METHODS: Prospective, open label, dual-cohort study with pathology-matched historical controls. The prospective experimental arms included two cohorts, composed of 51 eyes with recurrent PVR-related RRD and 58 eyes with primary RRD associated with high-risk features for developing PVR. Eyes in the experimental arms received 20 mg of isotretinoin by mouth once daily for 12 weeks starting the day after surgical repair. The primary outcome measure was single surgery anatomical success rate at 3 months following the study surgery. RESULTS: The single surgery anatomic success rate was 78.4% versus 70.0% (p=0.358) in eyes with recurrent PVR-related retinal detachment exposed to isotretinoin versus historical controls, respectively. In eyes with RRD at high risk for developing PVR, the single surgery success rate was 84.5% versus 61.1% (p=0.005) for eyes exposed to isotretinoin versus historical controls, respectively. For eyes enrolled in the experimental arms, the most common isotretinoin-related side effects were dry skin/mucus membranes in 106 patients (97.2%), abnormal sleep/dreams in 4 patients (3.7%) and fatigue in 3 patients (2.8%). CONCLUSION: The management and prevention of PVR is challenging and complex. At the dose and duration given in this study, oral istotretinoin may reduce the risk of PVR-associated recurrent retinal detachment in eyes with primary RRD at high risk of developing PVR.
引用
- London NJS, Kaiser RS, Khan MA, et al. Determining the effect of low-dose isotretinoin on proliferative vitreoretinopathy: the DELIVER trial. Br J Ophthalmol. 2018. PMID: 30381390. doi:10.1136/bjophthalmol-2018-312839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。